MGNXNasdaqPharmaceutical PreparationsFiscal year ends December 31
MACROGENICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$3.33+0.08 (+2.46%)
Close on Oct 19, 2026
- Market cap
- $211.77M
- P/E (TTM)
- –
- Dividend yield
- –
MACROGENICS INC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Collaborative and other agreements | $87.18M | $119.92M | $30.55M | $119.30M | $63.29M | $97.76M | $62.02M | $58.64M | $155.52M | $86.58M | 58.3% | -27.3% |
| Contract manufacturing | $52.63M | $13.06M | $9.83M | $13.99M | $0 | $0 | – | – | – | – | 35.2% | +303.1% |
| Royalty revenue | $9.69M | $561.00K | $431.00K | $0 | $0 | – | – | – | – | – | 6.5% | +1626.6% |
| Product sales, net | $0 | $16.43M | $17.94M | $16.73M | $12.35M | $0 | $0 | – | – | – | 0.0% | -100.0% |
| Revenue from government agreements | – | $1.62M | $1.56M | $1.92M | $1.80M | $7.12M | $2.16M | $1.48M | $2.23M | $5.30M | – | – |
By region
From the segment and revenue-disaggregation notes of Macrogenics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.